Aligos Therapeutics, Inc. (NASDAQ:ALGS) Sees Significant Growth in Short Interest

Aligos Therapeutics, Inc. (NASDAQ:ALGS) saw a significant increase in short interest in the month of November. As of November 15th, there was short interest totalling 291,500 shares, an increase of 140.3% from the October 31st total of 121,300 shares. Currently, 11.5% of the company’s shares are sold short. Based on an average daily trading volume, of 266,300 shares, the short-interest ratio is currently 1.1 days.

Institutional Trading of Aligos Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Armistice Capital LLC lifted its stake in shares of Aligos Therapeutics by 5.3% in the second quarter. Armistice Capital LLC now owns 7,256,410 shares of the company’s stock valued at $2,540,000 after buying an additional 363,000 shares in the last quarter. Opaleye Management Inc. raised its holdings in shares of Aligos Therapeutics by 25.7% in the 1st quarter. Opaleye Management Inc. now owns 1,630,000 shares of the company’s stock worth $1,597,000 after acquiring an additional 333,000 shares during the last quarter. Finally, Acadian Asset Management LLC lifted its position in Aligos Therapeutics by 26.1% in the 2nd quarter. Acadian Asset Management LLC now owns 829,485 shares of the company’s stock valued at $289,000 after acquiring an additional 171,490 shares in the last quarter. 60.43% of the stock is owned by institutional investors.

Aligos Therapeutics Trading Up 11.0 %

Shares of Aligos Therapeutics stock opened at $25.51 on Friday. The business has a 50-day moving average price of $11.83 and a two-hundred day moving average price of $12.67. Aligos Therapeutics has a 1-year low of $6.76 and a 1-year high of $30.00. The company has a market cap of $91.58 million, a P/E ratio of -1.92 and a beta of 2.11.

Aligos Therapeutics (NASDAQ:ALGS) last released its earnings results on Wednesday, November 6th. The company reported ($3.07) EPS for the quarter, missing the consensus estimate of ($2.15) by ($0.92). The business had revenue of $1.27 million for the quarter, compared to analyst estimates of $1.00 million. Aligos Therapeutics had a negative return on equity of 114.34% and a negative net margin of 1,283.19%. During the same period in the prior year, the business earned ($10.25) EPS. Equities research analysts forecast that Aligos Therapeutics will post -10.36 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and issued a $75.00 price target on shares of Aligos Therapeutics in a research report on Thursday, November 7th.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).